BC010326 Activators comprise a range of chemical compounds that indirectly foster the functional activity of BC010326 through a multitude of signaling pathways. Compounds like Forskolin and Sphingosine-1-phosphate operate through cyclic AMP and sphingosine-1-phosphate receptors, respectively, augmenting intracellular cascades that may lead to the activation of protein kinase A and G protein-coupled receptor pathways, which in turn can phosphorylate BC010326 or its interacting partners, thereby enhancing BC010326 function. Genistein and the polyphenol compound Epigallocatechin gallate (EGCG) serve as kinase inhibitors, which can indirectly increase BC010326 activity by preventing the phosphorylation of proteins that may act as negative regulators of BC010326. Likewise, PI3K inhibitors such as LY294002 and Wortmannin may bolster BC010326 action by mitigating the negative feedback on BC010326-associated pathways, thus promoting the protein's functional role.
Furthermore, the activity of BC010326 is indirectly supported by modulators of MAPK signaling, such as SB203580 and U0126, which inhibit p38 and MEK1/2, respectively, potentially alleviating inhibitory control over BC010326-related proteins and enhancing BC010326 activity. Phorbol 12-myristate 13-acetate (PMA) acts as a potent PKC activator, which is known to phosphorylate a wide range of target proteins, potentially including BC010326 or proteins within its signaling pathway, thereby enhancing BC010326's functional role. A23187, as a calcium ionophore, and Thapsigargin, as a SERCA pump inhibitor, both contribute to elevating intracellular calcium levels, which can activate calcium-dependent proteins and pathways that may lead to the enhancement of BC010326 activity. Staurosporine, despite its broad kinase inhibition profile, might preferentially activate BC010326 pathways by selectively inhibiting kinases that are negative regulators of BC010326. Collectively, these BC010326 Activators, through their targeted effects on cellular signaling, facilitate the enhancement of BC010326 mediated functions without the need for upregulating its expression or direct activation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which is involved in numerous signaling cascades. PKC can phosphorylate BC010326 or associated regulatory proteins, leading to an enhancement of BC010326 activity. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
S1P binds to its G protein-coupled receptors, which can lead to downstream activation of signaling pathways that influence the activity of BC010326, such as through kinase-mediated phosphorylation. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein, as a tyrosine kinase inhibitor, can prevent the phosphorylation of proteins that may negatively regulate BC010326, thus indirectly enhancing its activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits PI3K, which can lead to a reduced negative feedback on BC010326-related pathways, thereby enhancing the activity of BC010326. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor that can indirectly enhance BC010326 activity by similar mechanisms as LY294002, by reducing competitive signaling pathways. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 inhibits p38 MAPK, which may reduce the inhibitory phosphorylation of proteins associated with BC010326, thus enhancing BC010326 activity. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 acts as a calcium ionophore, increasing intracellular calcium and potentially enhancing BC010326 activity by activating calcium-dependent signaling pathways. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG can inhibit several kinases, which could reduce inhibitory phosphorylation of proteins in BC010326-related pathways, thus enhancing BC010326 activity. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine, though a broad-spectrum kinase inhibitor, may lead to selective enhancement of BC010326 pathways by inhibiting kinases that negatively regulate BC010326. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin inhibits the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA), leading to increased cytosolic calcium levels, which may enhance BC010326 activity via calcium-dependent pathways. | ||||||